Moreover, the study conducted by Gonzales in 2015 underlines the possible role of ACPA, observing that ACPA-positive RA patients had a significantly higher mean percentage of sites with ABL greater than 20% compared to OA controls [51]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.